• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Exelon Patch patent expiration





Clearly the future is Primary Care.

Wrong Resp/Derm is the place to be! How many times have they said that just prior to self destruction? In September 2007 the day after all the Famvir meetings Famvir went generic while we were at the meeting. By December 2007 Resp/Derm no longer existed. Then we were Specialty Meds for 2008. Then we were General Meds in 2009 and was blessed to have Rich Scat as the great leader in Long Island with a layoff in December 2010 followed by a larger layoff in April 2012 and now another layoff in February 2014. We are left with Exelon Patch as the star we hook our fortunes to. How sad! Who could ever imagined this scenario?
 
Last edited by a moderator: